Biodexa Pharmaceuticals (BDRX) announced the enrolment of the first three patients by the University of Bonn, Germany into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis, a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial
- Biodexa Pharmaceuticals files to sell 3.38M units
- Biodexa Pharmaceuticals’ Phase 3 Serenta Trial Approved in Europe
- Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP
- Biodexa Pharmaceuticals’ Phase 3 Trial Update: A Potential Breakthrough in FAP Treatment